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Multi-column continuous chromatography (MCC) offers significant economic advantages over traditional batch 
methods for purification of monoclonal antibodies (mAbs), including increased resin capacity utilization, smaller 
columns, reduced buffer consumption, and faster process time. Whereas the high cost of Protein A media makes 
the capture step a primary target to apply MCC, continuous polishing also provides potential advantages for pro-
cess continuity and product quality.  
We used the Semba ProPDTM System to investigate a continuous DSP concept that takes advantage of the 
extremely high MCC productivity of the Protein A capture step made possible by using concentrated culture fluid, 
high dynamic binding and flow capacity resin, and sufficient column number. Following low pH hold and neutral-
ization, polishing steps are performed on a second MCC unit. Typically two polishing steps are required; these 
can be sequentially performed on the same system using appropriate column configurations and method opera-
tions.  
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BAtch uSP – contInuouS dSP chromAtogrAPhy concePt
Process design begins with determination of the feed duration, which is governed by the mAb titer, column 
dimensions, residence time, binding capacity, and flow properties of the resin. Use of 3 columns in the capture 
zone enables efficient resin utilization at short residence times, thereby increasing productivity. Column number 
and resin volume are optimized to relieve scheduling constraints experienced at high mAb titer (Godawat et al.) 
while maximizing cycling for single-use columns.
We used the Semba ProComposer™ application to create MCC methods that incorporate the target design 
criteria, and then tested them on the ProPD System using 2–10 g of feed material.
SummAry
1. Typical mAb purification platform batch chromatography steps have been converted to continuous multi-
column chromatography using Semba ProComposer™ software and then quickly and easily tested with the 
ProPD™ System.
2. Protein A capture productivities of 80-112 g/L/h were obtained using three different CHO culture fluid feed 
streams with mAb titers of 7-10.8 g/L and eight 5-ml columns.
3. Scaled comparison of a typical 2,000 L, 5 g/L mAb titer Protein A batch capture versus a continuous 8-column 
process showed significant reduction in consumables and overall processing time. Protein A resin volume 
was decreased 7.1-fold, buffer volume decreased 2.9-fold, process time decreased from 7 days to 1 day, and 
process productivity increased 14-fold.
4. Polishing by continuous 2-column AEX and 6-column Mixed Mode required only three buffers for both pro-
cesses, and reduced aggregate to 1.5%, HCP by 2.6 logs, DNA to 19 pg/mg, and residual Protein A to < 0.1 
ppm.
5. Step yields for the continuous Protein A capture, AEX, and MM processes were all > 90% with a final overall 
yield of 77% . 
PolIShIng
We used the post-Protein A virus-inactivated and neutralized pool as Unit 2 Feed for polishing by anion ex-
change in a flow-through operation, followed by cation exchange or mixed mode in a bind-elute operation. The 
Semba ProPD unit was configured to run the AEX step with 2 columns. The AEX flow through served as the Feed 
for the 6-column bind-elute run on the same unit. The same buffer formulations were used for chase, wash, strip 
and equilibration for both methods. Protein A wash and elution conditions were adjusted so that the conductivity 






Six pumps: choice of 36, 100, 300 ml/min
Four each UV-VIS, conductivity, & pH sensors
1 mm, 1.5 mm, 2.4 mm valve block flow paths
Harvest-clarification 2–4 X TFF concentration 1,000–2,000 L








1 or 2-Step polishing:
AEX, CEX, MM
Product transfer @ 
start of each cycle Unit 2 Feed







Clarification 2,622 100 – – 27,240 –
Protein A Capture3 2,346 90 4.7 1.7 218 0.98
Anion Exchange4 2,198 94 (845) 3.5 2.2 116 0.37
Mixed Mode5 2,025 92 (775) 1.5 2.6 19 <0.1
mAb Feed g/L g/cycle Recovery Productivity
1 7.0 2.3/43 min 92.5% 80 g/L/h
2 7.9 2.4/43 min 90.1% 88 g/L/h
3 10.8 2.4/32 min 90.5% 112 g/L/h
1. Non-chromatographic operations included low pH virus inactivation and filtration
2. 7.9 mg/ml mAb from CHO culture (270,000 ppm HCP)
3. TOYOPEARL® AF rProtein A HC 650F 5-ml columns (Tosoh Bioscience)
4. Sartobind STIC®-PA 1-ml cartridges (Sartorius)
5. Nuvia™ C-Prime® 1-ml columns (Bio-Rad)
Eight 5-ml TOYOPEARL® AF rProtein A HC columns (Tosoh Bioscience)
0.5 min residence time
3 columns in capture zone
Sequential polishing on the same 8-column ProPD unit:  
2-column AEX flow through followed by 6-column Mixed Mode bind-elute
P&ID (top)
Process Ribbon (bottom)
2-column continuous AEX flow through 6-column continuous CEX/MM bind-elute
Semba ProGMPTM System
Same as above, except:
Six pumps: 2500 ml/min
Single use valve block, sensors and flow path
Parameter Batch Semba ProGMP
Columns 60 x 20 cm (1 column)
14 x 6.5 cm 
(8 columns)
Protein A resin volume 56.6 L 8 L
Buffer volume 12,271 L 4,303 L
Feed flow rate 8.3 L/min 2 L/min
Residence time 6.8 min 0.5 min
Cycle time 5 h 1.0 h
Cycles required 7 (1 cycle/day) 20 (1 day continuous)
Process time 35 h 20 h
Productivity 4.2 g/L/h 59 g/L/h
Estimated parameters for Protein A capture processing 2,000 L at 5 g/L mAb titer
Design Consideration Target
mAb concentration in process stream > 5 g/L
Process volume and time constraints 50–2,000 L in 2–20 h
Chromatography media capacity and flow properties > 50 mg/ml DBC > 600 cm/h
Column dimensions Compatible with > 600 cm/h  @ < 6 bar
Number of columns 4–8, dependent on titer; avoid feed continuity constraint
Cycle number per campaign 10–50
Buffer compatibility Minimize dilution and  number of buffers required
Linking downstream process steps
Transfers synchronized to MCC cycle 
time; Automation of viral inactivation, 
PAT and polishing
biologics
